Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Thursday. $253.22 million flowed into the stock on the tick-up and $170.59 million flowed out of the stock on the tick-down, for a money net flow of $82.63 million into the stock. Of all equities tracked, Johnson & Johnson had the highest net in-flow for the day. Johnson & Johnson traded down ($0.59) for the day and closed at $120.72

Several equities analysts have recently commented on JNJ shares. Wells Fargo & Co. restated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, June 6th. Deutsche Bank AG restated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, May 19th. Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research report on Friday, August 5th. Finally, BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $119.30.

The firm has a 50-day moving average of $123.40 and a 200-day moving average of $113.73. The firm has a market cap of $328.09 billion and a PE ratio of 22.35.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. Analysts forecast that Johnson & Johnson will post $6.69 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, August 19th. Stockholders of record on Friday, August 5th were issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 0.97%.

In other news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $115.79, for a total transaction of $347,370.00. Following the completion of the transaction, the chief accounting officer now owns 28,725 shares in the company, valued at approximately $3,326,067.75. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently modified their holdings of the company. Heritage Wealth Advisors boosted its position in shares of Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock valued at $1,021,000 after buying an additional 317 shares in the last quarter. Lourd Capital LLC boosted its position in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock valued at $1,142,000 after buying an additional 851 shares in the last quarter. Eidelman Virant Capital boosted its position in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock valued at $1,193,000 after buying an additional 1,231 shares in the last quarter. Private Capital Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $1,428,000. Finally, Holderness Investments Co. boosted its position in shares of Johnson & Johnson by 2.1% in the fourth quarter. Holderness Investments Co. now owns 14,942 shares of the company’s stock valued at $1,535,000 after buying an additional 302 shares in the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.